Sprycel News and Research

RSS
On June 28, 2006, the FDA granted accelerated approval of SPRYCEL for the treatment of adults in all three phases of CML (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec. The FDA also granted full approval of SPRYCEL for the treatment of adults with Ph+ ALL with resistance or intolerance to prior therapy. SPRYCEL is the first approved oral tyrosine kinase inhibitor that, at nanomolar concentrations, inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß kinases. The active ingredient of SPRYCEL is dasatinib. Dasatinib reduces the activity of one or more proteins responsible for the uncontrolled growth of the leukemia cells of patients with CML or Ph+ ALL.
FDA grants accelerated approval for Sprycel (dasatinib)

FDA grants accelerated approval for Sprycel (dasatinib)

New leukemia drug gives renewed hope to those battling drug resistance to the disease

New leukemia drug gives renewed hope to those battling drug resistance to the disease